肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：MEDI3617单药或联合化疗、贝伐单抗治疗晚期实体肿瘤

2018-06-29 MedSci MedSci原创

晚期实体肿瘤MEDI3617卡铂紫杉醇贝伐单抗
关注

CLIN CANCER RES近期发表了一篇文章， 研究选择性抗血管生成素-2（Ang2）单抗 MEDI3617单药或联合贝伐单抗或化疗的最大耐受剂量和安全性。

CLIN CANCER RES近期发表了一篇文章， 研究选择性抗血管生成素-2（Ang2）单抗 MEDI3617单药或联合贝伐单抗或化疗的最大耐受剂量和安全性。

该研究为评估晚期实体肿瘤患者的Ⅰ/Ⅰb期，多中心，剂量递增和拓展研究。患者接受静脉MEDI3617单药（5-1500mg 三周（Q3W ））联合贝伐单抗每2周（Q2W）或Q3W，紫杉醇每周或卡铂加紫杉醇Q3W。剂量拓展包括铂类耐药的卵巢癌单药治疗队列和贝伐单抗耐药恶性胶质瘤的联合贝伐单抗治疗队列。研究共纳入116例患者。未达到最终的最大耐受剂量（单药或联合治疗）。MEDI3617药代动力学呈线性，300mg Q3W剂量时外周Ang2结合达到最大程度。MEDI3617单药安全性良好，但在晚期卵巢癌中安全性较差（出现3级水肿相关不良反应）。此外，MEDI3617联合化疗或贝伐单抗耐受性良好。卵巢癌和胶质瘤单药单药剂量递增队列的总缓解率分别为6%和0%。

文章最后认为，除了卵巢癌，MEDI3617单药治疗推荐剂量为1500mg Q3W或1000mg Q2W。联合其他Ang2抑制剂时也会出现外周水肿，但是卵巢癌中出现的严重程度和持续时间表明该症状可能会作为这类患者新的临床安全性指标。由于其临床活性有限，终止了MEDI3617的研究。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754577, encodeId=c6c41e54577d2, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Fri Mar 29 15:42:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379158, encodeId=046713e915826, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411725, encodeId=1fad1411e253a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477023, encodeId=b25014e70231e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608908, encodeId=98981608908e1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2019-03-29 30397616

    #晚期实体肿瘤#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1754577, encodeId=c6c41e54577d2, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Fri Mar 29 15:42:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379158, encodeId=046713e915826, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411725, encodeId=1fad1411e253a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477023, encodeId=b25014e70231e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608908, encodeId=98981608908e1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 weiz

    #实体肿瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1754577, encodeId=c6c41e54577d2, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Fri Mar 29 15:42:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379158, encodeId=046713e915826, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411725, encodeId=1fad1411e253a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477023, encodeId=b25014e70231e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608908, encodeId=98981608908e1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 oliver170

    #联合化疗#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1754577, encodeId=c6c41e54577d2, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Fri Mar 29 15:42:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379158, encodeId=046713e915826, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411725, encodeId=1fad1411e253a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477023, encodeId=b25014e70231e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608908, encodeId=98981608908e1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 sunrural_42825359

    #贝伐#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1754577, encodeId=c6c41e54577d2, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Fri Mar 29 15:42:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379158, encodeId=046713e915826, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411725, encodeId=1fad1411e253a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477023, encodeId=b25014e70231e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608908, encodeId=98981608908e1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 01 01:42:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 ms3994565386320060

    #Med#

    0

相关资讯

CLIN CANCER RES：M7824治疗晚期实体肿瘤

人们对PD-1/PD-L1靶向治疗的热情正逐渐降温，部分原因便是该疗法仅在一部分患者中证明有效。为了增加反应率，许多进行中的临床试验均在评估抗PD-1/PD-L1药物与其他免疫治疗方式结合的效果。但是这些结合方式均存在限制。M7824是一种双功能融合蛋白，由抗PD-L1单抗与TGFβ“trap”融合而成。CLIN CANCER RES近期发表了一篇文章，报道M7824治疗晚期实体肿瘤的效果。

CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果

鞘氨醇激酶（SK1，SK2）通过调节有丝分裂及S1P影响肿瘤生长。ABC294640是第一种口服的SK2抑制剂。CLIN CANCER RES近期发表了一篇文章，报道了ABC294640治疗实体肿瘤的Ⅰ期临床试验结果。

CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤

IDO1催化色氨酸降解为NFK。IDO1在许多实体肿瘤中过表达，促使肿瘤逃逸机体免疫监视。CLIN CANCER RES近期发表了一篇文章，报道了IDO1选择性抑制剂epacadostat（INCB024360）Ⅰ期临床试验结果。

CLIN CANCER RES：Vanucizumab单药治疗晚期实体肿瘤

Vanucizumab是一种尚处于研究阶段的抗血管生产药物，靶向VEGF-A和Ang-2.CLIN CANCER RES近期发表了一篇文章，报道了Vanucizumab治疗晚期实体肿瘤的安全性，药代动力学，药效学及抗肿瘤活性。

JCO：Birabresib治疗晚期实体肿瘤

Birabresib（MK-8628/OTX015）是一种bromodomain抑制剂，在血液系统肿瘤中具有活性。JCO近期发表了一篇文章，研究Birabresib治疗去势抵抗前列腺癌，睾丸核蛋白中线癌（NMC）和非小细胞肺癌的安全性，有效性和药代动力学。